Paysign 과거 순이익 실적
과거 기준 점검 5/6
Paysign은 연평균 69.9%의 비율로 수입이 증가해 온 반면, Diversified Financial 산업은 수입이 13.5% 증가했습니다. 매출은 연평균 25.9%의 비율로 증가했습니다. Paysign의 자기자본이익률은 18.9%이고 순이익률은 11.4%입니다.
핵심 정보
69.87%
순이익 성장률
70.07%
주당순이익(EPS) 성장률
| Diversified Financial 산업 성장률 | 6.15% |
| 매출 성장률 | 25.89% |
| 자기자본이익률 | 18.91% |
| 순이익률 | 11.37% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.내러티브 업데이트 • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.내러티브 업데이트 • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.내러티브 업데이트 • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.분석 기사 • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...분석 기사 • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking Alpha분석 기사 • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
내러티브 업데이트 • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.분석 기사 • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...분석 기사 • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...분석 기사 • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
새로운 내러티브 • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.분석 기사 • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking Alpha분석 기사 • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...분석 기사 • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • Jan 25
Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Paysign가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 91 | 10 | 35 | 0 |
| 31 Dec 25 | 82 | 8 | 33 | 0 |
| 30 Sep 25 | 75 | 8 | 31 | 0 |
| 30 Jun 25 | 69 | 7 | 29 | 0 |
| 31 Mar 25 | 64 | 6 | 27 | 0 |
| 31 Dec 24 | 58 | 4 | 25 | 0 |
| 30 Sep 24 | 56 | 8 | 24 | 0 |
| 30 Jun 24 | 54 | 8 | 22 | 0 |
| 31 Mar 24 | 50 | 7 | 22 | 0 |
| 31 Dec 23 | 47 | 6 | 21 | 0 |
| 30 Sep 23 | 44 | 2 | 20 | 0 |
| 30 Jun 23 | 42 | 1 | 20 | 0 |
| 31 Mar 23 | 40 | 1 | 18 | 0 |
| 31 Dec 22 | 38 | 1 | 18 | 0 |
| 30 Sep 22 | 36 | 0 | 18 | 0 |
| 30 Jun 22 | 33 | -1 | 17 | 0 |
| 31 Mar 22 | 31 | -1 | 17 | 0 |
| 31 Dec 21 | 29 | -3 | 16 | 0 |
| 30 Sep 21 | 28 | -7 | 15 | 0 |
| 30 Jun 21 | 20 | -13 | 15 | 0 |
| 31 Mar 21 | 20 | -12 | 15 | 0 |
| 31 Dec 20 | 24 | -9 | 15 | 0 |
| 30 Sep 20 | 27 | -3 | 14 | 0 |
| 30 Jun 20 | 36 | 6 | 13 | 0 |
| 31 Mar 20 | 38 | 8 | 13 | 0 |
| 31 Dec 19 | 35 | 7 | 12 | 0 |
| 30 Sep 19 | 32 | 6 | 11 | 0 |
| 30 Jun 19 | 29 | 4 | 10 | 0 |
| 31 Mar 19 | 26 | 3 | 9 | 0 |
| 31 Dec 18 | 23 | 3 | 8 | 0 |
| 30 Sep 18 | 21 | 2 | 6 | 0 |
| 30 Jun 18 | 19 | 2 | 6 | 0 |
| 31 Mar 18 | 17 | 2 | 5 | 0 |
| 31 Dec 17 | 15 | 2 | 4 | 0 |
| 30 Sep 17 | 14 | 2 | 3 | 0 |
| 30 Jun 17 | 12 | 2 | 3 | 0 |
| 31 Mar 17 | 11 | 2 | 3 | 0 |
| 31 Dec 16 | 10 | 1 | 3 | 0 |
| 30 Sep 16 | 10 | 1 | 3 | 0 |
| 30 Jun 16 | 9 | -2 | 3 | 0 |
| 31 Mar 16 | 9 | -2 | 4 | 0 |
| 31 Dec 15 | 8 | -2 | 4 | 0 |
| 30 Sep 15 | 11 | 0 | 4 | 0 |
| 30 Jun 15 | 11 | 3 | 3 | 0 |
양질의 수익: PAYS는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: PAYS의 현재 순 이익률 (11.4%)은 지난해 (9.6%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: PAYS는 지난 5년 동안 흑자전환하며 연평균 69.9%의 수익 성장을 기록했습니다.
성장 가속화: 지난 1년간 PAYS 의 수익 증가율(70.8%)은 연간 평균(69.9%)을 초과합니다.
수익 대 산업: PAYS의 지난 1년 수익 증가율(70.8%)은 Diversified Financial 업계의 8.6%를 상회했습니다.
자기자본이익률
높은 ROE: PAYS의 자본 수익률(18.9%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 22:58 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Paysign, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |